The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Palexia SR 100 mg prolonged-release tablets

PCO Manufacturing Ltd.PPA0465/458/003

Main Information

Trade NamePalexia SR 100 mg prolonged-release tablets
Active SubstancesTapentadol
Dosage FormProlonged-release tablet
Licence HolderPCO Manufacturing Ltd.
Licence NumberPPA0465/458/003

Group Information

ATC CodeN02AX06 tapentadol


Licence Issued04/12/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 to the Misuse of Drugs Regulations 2017
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back